TMCnet News
Global Pruritus Market 2018-2027: Insights, Epidemiology and Forecasts - Trends and Opportunities - ResearchAndMarkets.comThe "Pruritus - Market Insights, Epidemiology and Market Forecasts to 2027" report has been added to ResearchAndMarkets.com's offering. According to research, the global market of Pruritus in Atopic Dermatitis was estimated to be USD 1.8 billion in 2016, and is expected to increase with a significant growth rate from 2016-2027. This report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of Pruritus in Atopic Dermatitis in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom), and Japan. The report provides the current treatment practices, emerging drugs, market share of the individual therapies, current and forecasted market size of Atopic Dermatitis as well as Pruritus in Atopic Dermatitis from 2016 to 2027 segmented by seven major markets. The report also covers current reatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. According to research, the prevalent population of Pruritus in Atopic Dermatitis in 7 major markets was estimated to be 20.58 Million [7MM] in 2016 and, is expected to increase with a significant growth rate from 2016-2027. United States accounts for the highest Cases, followed by EU5 (Germany, France, Italy, Spain & UK) and Japan. Among EU5, Germany has been reported to have the highest prevalent population of pruritus in atopic dermatitis. The upcoming therapies for the treatment of Pruritus in Atopic Dermatitis mainly include [Nemolizumab (Galderma Pharma), Tralokinumab (LEO Pharma), Tradipitant (Vanda Pharmaceuticals), ZPL-389 (Novartis), NST (News - Alert)-141 (Nippon Shinyaku), etc., have been covered in the report. Companies Mentioned
For more information about this report visit https://www.researchandmarkets.com/research/b6xqkc/global_pruritus?w=4 View source version on businesswire.com: http://www.businesswire.com/news/home/20180222006010/en/ |
